Concepedia

Author

Mary Lou Ernest

University of California, San Francisco

Also Known As

M L Ernest, M. L. ERNEST, Mary Lou Ernest

14

Publications

691

Citations

10

H-Index

33

Concepts

All Affiliations

University of California, San FranciscoLoyola University ChicagoTufts UniversityMontefiore Medical CenterYeshiva University
ML

About

Mary Lou Ernest is an author at University of California, San Francisco specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

185

2

Public Health

2

2

118

3

Health Sciences

1

1

31

4

Nursing

1

1

67

5

Endocrinology

1

1

51

Mary Lou Ernest

×

10

Publications

676

Citations

10

H-Index

YearCitations

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

Joseph A. Sparano, Richard I. Fisher, Margaret C. Sunderland,

Journal of Clinical Oncology

1993

177

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

Michael B. Atkins, K R O'Boyle, Jeff Sosman,

Journal of Clinical Oncology

1994

129

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

Janice P. Dutcher, Richard I. Fisher, Geoffrey R. Weiss,

PubMed

1997

77

Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma

Kim Margolin, Frederick R. Aronson, Mario Sznol,

Journal of Immunotherapy

1994

69

SIS.NET: A randomized controlled trial evaluating a web‐based system for symptom management after treatment of breast cancer

Alyse Wheelock, Meredith Bock, Eva L. Martin,

Cancer

2014

67

Hypogonadal impotence treated by transdermal testosterone

R. Dale McClure, Raymond Oses, Mary Lou Ernest

Urology

1991

51

Phase II Trials of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Breast Carcinoma and Carcinoma of the Lung, Ovary, and Pancreas and Other Tumors

Joseph A. Sparano, Richard I. Fisher, Geoffrey R. Weiss,

Journal of Immunotherapy

1994

36

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

Jeffrey A. Sosman, Frederick R. Aronson, Mario Sznol,

PubMed

1997

31

A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium

Eric J. Small, L. Fippin, Mary Lou Ernest,

Cancer

1996

24

A phase II study of constant‐infusion floxuridine for the treatment of metastatic renal cell carcinoma

Mary Wilkinson, John Frye, Eric J. Small,

Cancer

1993

15

Page 1